Compare Genuine Parts Company (GPC) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs Incyte Corporation — how do they compare? Genuine Parts Company trades at $135.22 (market cap $18.62B), while Incyte Corporation trades at $120.77 (market cap $24.54B). The key difference: Incyte Corporation is the larger of the two by market cap, and Genuine Parts Company pays a 3.15% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| GPC | INCY | |
|---|---|---|
Market Cap | $18.62B | $24.54B |
Sector | Consumer Cyclical | Health |
52-Week High | $149.26 | $129.93 |
52-Week Low | $92.47 | $81.66 |
Enterprise Value | $24.72B | $20.04B |
Dividend Yield | 3.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPC trades at $133.89, down 0.48% today, with a bullish technical outlook from moving averages but overbought RSI signals. Recent Q2 2026 earnings beat expectations with EPS of $2.15 versus $2.08 expected, driven by 6% sales growth. The company maintains a dividend payout, with a $1.06 dividend declared for H1 2026. Valuation shows a high P/E of 540.36 but a reasonable P/S of 0.75, while net income margins remain thin at 0.13% for 2025.
Outlook is mixed: analyst consensus targets $148.67 with 43% buy ratings, but profitability challenges and rising debt-to-asset ratios pose risks. The stock's proximity to its 52-week high suggests limited near-term upside, requiring careful monitoring of margin improvements and industrial segment performance to justify further gains.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
